K2 HealthVentures
K2 HealthVentures is an alternative investment firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed K2 HealthVentures Information
Geographic Data
Address: 855 Boylston Street
City: Boston
State: MA
Zip: 02116
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$400M
Social
Linkedin
Crunchbase
Metrics
3,745,107Website Global Rank
3,450Website Monthly Traffic
Twitter Followers
Description
K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. The investment team is comprised of collaborative, experienced professionals with diverse backgrounds in finance and operations, as well as deep domain knowledge across various healthcare sectors. A uniquely flexible, permanent capital structure enables the firm to provide creative, adaptive financing solutions and meet the evolving capital needs of its portfolio companies as they grow. K2HV is driven by dual goals of Profit and Purpose – aiming to fuel the growth of innovative companies that will ultimately improve the lives of patients and giving a percentage of investment profits back to underserved areas in healthcare.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2022 | DispatchHealth | Debt Financing | - |
| 12/2020 | Click Therapeutics | Debt Financing | 0 |
| 5/2021 | VBI Vaccines | Post-IPO Debt | 12M |
| 11/2019 | Surface Oncology | Debt Financing | 25M |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 9/2022 | TScan Therapeutics | Post-IPO Debt | 60M |
| 9/2021 | Aptinyx | Post-IPO Debt | 50M |
| 10/2021 | Invaio Sciences | Debt Financing | 0 |
| 7/2022 | Elevation Oncology | Post-IPO Debt | 50M |
| 4/2022 | Oncorus | Post-IPO Debt | 20M |
| 1/2020 | Companion Medical | Debt Financing | 27.5M |
| 7/2022 | Inozyme | Post-IPO Debt | 70M |
| 10/2022 | Inari | Debt Financing | - |
| 4/2023 | Vedanta Biosciences | Series E | 0 |
| 9/2022 | VBI Vaccines | Post-IPO Debt | 100M |
| 11/2021 | Platelet BioGenesis | Series B | 75.5M |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 8/2021 | Cricket Health | Series B | 0 |
| 9/2020 | Colorescience | Debt | 30M |
| 9/2019 | Metacrine | Debt Financing | 50M |
| 4/2020 | Inari | Debt Financing | 45M |
| 5/2020 | VBI Vaccines | Post-IPO Debt | 50M |
| 1/2023 | Alto Neuroscience | Debt Financing | 35M |
| 7/2022 | Elevation Oncology | Post-IPO Debt | 0 |
| 7/2022 | Inozyme | Post-IPO Debt | 0 |
| 4/2022 | Oncorus | Post-IPO Debt | 0 |
| 11/2021 | Platelet BioGenesis | Series B | 0 |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 10/2021 | Invaio Sciences | Debt Financing | 0 |
| 9/2021 | Aptinyx | Post-IPO Debt | 0 |
| 8/2021 | Cricket Health | Series B | 0 |
| 5/2021 | VBI Vaccines | Post-IPO Debt | 0 |
| 12/2020 | Click Therapeutics | Debt Financing | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
